Skip to main content

Table 2 Clinical features of the study patients according to use of antibiotic therapy

From: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

FeatureAntibiotic therapy (n = 569)No antibiotic therapy (n = 257)p
IMDC, n (%)267 (46.9)167 (65.0)< 0.001
Mean duration of IMDC symptoms, days (SD)32 (150)18 (102)0.290
Hospitalization, n (%)168 (62.9)63 (37.7)< 0.001
Mean duration of hospitalization, days (SD)8 (7)7 (5)0.143
ICU admission, n (%)10 (1.8)1 (0.3)0.038
Grade of colitis, n (%)  0.022
 142 (20.7)32 (27.6) 
 290 (44.3)60 (51.7) 
 365 (32.0)19 (16.4) 
 46 (3.0)5 (4.3) 
Grade of diarrhea, n (%)  0.098
 177 (28.8)52 (31.1) 
 269 (25.8)51 (30.5) 
 3103 (38.3)61 (36.5) 
 418 (6.7)3 (1.8) 
Mean duration of steroid administration, days (SD)52 (44)63 (79)0.147
Infliximab/vedolizumab administration, n (%)52 (19.5)31 (18.6)0.900
Recurrence of IMDC, n (%)42 (15.4)41 (24.6)0.025